Cargando…

Administration costs of intravenous biologic drugs for rheumatoid arthritis

BACKGROUND: Cost-effectiveness studies explicitly reporting infusion times, drug-specific administration costs for infusions or real-payer intravenous drug cost are few in number. Yet, administration costs for infusions are needed in the health economic evaluations assessing intravenously-administer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soini, Erkki J, Leussu, Miina, Hallinen, Taru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825225/ https://www.ncbi.nlm.nih.gov/pubmed/24255834 http://dx.doi.org/10.1186/2193-1801-2-531

Ejemplares similares

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
por: Soini, Erkki J., et al.
Publicado: (2015)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
por: Hallinen, Taru, et al.
Publicado: (2023)

Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management
por: Soini, Erkki, et al.
Publicado: (2018)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data
por: Hallinen, Taru, et al.
Publicado: (2014)

Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders
por: Hallinen, Taru, et al.
Publicado: (2012)

Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
por: Stavrakas, Spyros, et al.
Publicado: (2011)

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
por: Soini, Erkki, et al.
Publicado: (2017)

Intravenous pamidronate for refractory rheumatoid arthritis
por: Salesi, Mansour, et al.
Publicado: (2012)

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Joensuu, Jaana T., et al.
Publicado: (2015)

Bone Effects of Biologic Drugs in Rheumatoid Arthritis
por: Corrado, Addolorata, et al.
Publicado: (2013)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2016)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Genetics of rheumatoid arthritis contributes to biology and drug discovery
por: Okada, Yukinori, et al.
Publicado: (2013)

Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis
por: Bolge, Susan C, et al.
Publicado: (2017)

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
por: Birkner, Benjamin, et al.
Publicado: (2020)

Evaluating the administration costs of biologic drugs: development of a cost algorithm
por: Tetteh, Ebenezer K, et al.
Publicado: (2014)

Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland
por: Puolitaival, Antti, et al.
Publicado: (2022)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
por: Theidel, Ulrike, et al.
Publicado: (2017)

Indirect costs of rheumatoid arthritis
por: Raciborski, Filip, et al.
Publicado: (2015)

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
por: Bitoun, Samuel, et al.
Publicado: (2023)

Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
por: Mulhearn, Ben, et al.
Publicado: (2019)

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
por: Chastek, Benjamin, et al.
Publicado: (2017)

Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis
por: Huynh, Tuan Khai, et al.
Publicado: (2014)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania
por: Codreanu, Cătălin, et al.
Publicado: (2019)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Response measures influence comparative effectiveness of biological drugs in rheumatoid arthritis
por: Canhao, Helena, et al.
Publicado: (2012)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation
por: Lamela-Gómez, Iván, et al.
Publicado: (2023)

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey
por: Baser, Onur, et al.
Publicado: (2013)

Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis
por: Hopson, Sari, et al.
Publicado: (2016)

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2015)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4hbphf4nvkmjr93s2900530g3c